The University of Chicago Header Logo

Connection

Mary Eileen Dolan to Genome-Wide Association Study

Back to Details
This is a "connection" page, showing publications Mary Eileen Dolan has written about Genome-Wide Association Study.
Mary Eileen Dolan
Connection Strength
4.148
Genome-Wide Association Study
  1. Clinical and Genome-wide Analysis of Cisplatin-induced Tinnitus Implicates Novel Ototoxic Mechanisms. Clin Cancer Res. 2019 07 01; 25(13):4104-4116.
    View in: PubMed
    Score: 0.398
  2. Clinical and Genome-Wide Analysis of Cisplatin-Induced Peripheral Neuropathy in Survivors of Adult-Onset Cancer. Clin Cancer Res. 2017 Oct 01; 23(19):5757-5768.
    View in: PubMed
    Score: 0.351
  3. Genome-Wide Association Studies of Chemotherapeutic Toxicities: Genomics of Inequality. Clin Cancer Res. 2017 Aug 01; 23(15):4010-4019.
    View in: PubMed
    Score: 0.347
  4. Integrating cell-based and clinical genome-wide studies to identify genetic variants contributing to treatment failure in neuroblastoma patients. Clin Pharmacol Ther. 2014 Jun; 95(6):644-52.
    View in: PubMed
    Score: 0.279
  5. Integration of cell line and clinical trial genome-wide analyses supports a polygenic architecture of Paclitaxel-induced sensory peripheral neuropathy. Clin Cancer Res. 2013 Jan 15; 19(2):491-9.
    View in: PubMed
    Score: 0.256
  6. Genome-wide local ancestry approach identifies genes and variants associated with chemotherapeutic susceptibility in African Americans. PLoS One. 2011; 6(7):e21920.
    View in: PubMed
    Score: 0.232
  7. Use of cell lines in the investigation of pharmacogenetic loci. Curr Pharm Des. 2009; 15(32):3782-95.
    View in: PubMed
    Score: 0.195
  8. Pharmacogenomics of cisplatin-induced neurotoxicities: Hearing loss, tinnitus, and peripheral sensory neuropathy. Cancer Med. 2022 07; 11(14):2801-2816.
    View in: PubMed
    Score: 0.122
  9. Clinical and genetic risk factors for radiation-associated ototoxicity: A report from the Childhood Cancer Survivor Study and the St. Jude Lifetime Cohort. Cancer. 2021 Nov 01; 127(21):4091-4102.
    View in: PubMed
    Score: 0.116
  10. Clinical and Genome-Wide Analysis of Multiple Severe Cisplatin-Induced Neurotoxicities in Adult-Onset Cancer Survivors. Clin Cancer Res. 2020 12 15; 26(24):6550-6558.
    View in: PubMed
    Score: 0.110
  11. Clinical and Genome-Wide Analysis of Serum Platinum Levels after Cisplatin-Based Chemotherapy. Clin Cancer Res. 2019 10 01; 25(19):5913-5924.
    View in: PubMed
    Score: 0.101
  12. Genetic and Modifiable Risk Factors Contributing to Cisplatin-induced Toxicities. Clin Cancer Res. 2019 02 15; 25(4):1147-1155.
    View in: PubMed
    Score: 0.096
  13. Integration of genetic and functional genomics data to uncover chemotherapeutic induced cytotoxicity. Pharmacogenomics J. 2019 04; 19(2):178-190.
    View in: PubMed
    Score: 0.094
  14. Genetic Variants Contributing to Colistin Cytotoxicity: Identification of TGIF1 and HOXD10 Using a Population Genomics Approach. Int J Mol Sci. 2017 Mar 18; 18(3).
    View in: PubMed
    Score: 0.086
  15. Pharmacoethnicity in Paclitaxel-Induced Sensory Peripheral Neuropathy. Clin Cancer Res. 2015 Oct 01; 21(19):4337-46.
    View in: PubMed
    Score: 0.076
  16. Protein quantitative trait loci identify novel candidates modulating cellular response to chemotherapy. PLoS Genet. 2014 Apr; 10(4):e1004192.
    View in: PubMed
    Score: 0.070
  17. EPS8 inhibition increases cisplatin sensitivity in lung cancer cells. PLoS One. 2013; 8(12):e82220.
    View in: PubMed
    Score: 0.069
  18. Genetic and epigenetic variants contributing to clofarabine cytotoxicity. Hum Mol Genet. 2013 Oct 01; 22(19):4007-20.
    View in: PubMed
    Score: 0.066
  19. Comprehensive genetic analysis of cytarabine sensitivity in a cell-based model identifies polymorphisms associated with outcome in AML patients. Blood. 2013 May 23; 121(21):4366-76.
    View in: PubMed
    Score: 0.065
  20. Functional consequences of PRPF39 on distant genes and cisplatin sensitivity. Hum Mol Genet. 2012 Oct 01; 21(19):4348-55.
    View in: PubMed
    Score: 0.062
  21. Identification of novel germline polymorphisms governing capecitabine sensitivity. Cancer. 2012 Aug 15; 118(16):4063-73.
    View in: PubMed
    Score: 0.060
  22. Lymphoblastoid cell lines in pharmacogenomic discovery and clinical translation. Pharmacogenomics. 2012 Jan; 13(1):55-70.
    View in: PubMed
    Score: 0.060
  23. An eQTL-based method identifies CTTN and ZMAT3 as pemetrexed susceptibility markers. Hum Mol Genet. 2012 Apr 01; 21(7):1470-80.
    View in: PubMed
    Score: 0.060
  24. Genome-wide meta-analysis identifies variants associated with platinating agent susceptibility across populations. Pharmacogenomics J. 2013 Feb; 13(1):35-43.
    View in: PubMed
    Score: 0.059
  25. Chemotherapeutic-induced apoptosis: a phenotype for pharmacogenomics studies. Pharmacogenet Genomics. 2011 Aug; 21(8):476-88.
    View in: PubMed
    Score: 0.058
  26. Population differences in microRNA expression and biological implications. RNA Biol. 2011 Jul-Aug; 8(4):692-701.
    View in: PubMed
    Score: 0.058
  27. Platinum sensitivity-related germline polymorphism discovered via a cell-based approach and analysis of its association with outcome in ovarian cancer patients. Clin Cancer Res. 2011 Aug 15; 17(16):5490-500.
    View in: PubMed
    Score: 0.058
  28. The use of genomic information to optimize cancer chemotherapy. Semin Oncol. 2011 Apr; 38(2):186-95.
    View in: PubMed
    Score: 0.057
  29. Chemotherapeutic drug susceptibility associated SNPs are enriched in expression quantitative trait loci. Proc Natl Acad Sci U S A. 2010 May 18; 107(20):9287-92.
    View in: PubMed
    Score: 0.054
  30. Trait-associated SNPs are more likely to be eQTLs: annotation to enhance discovery from GWAS. PLoS Genet. 2010 Apr 01; 6(4):e1000888.
    View in: PubMed
    Score: 0.053
  31. Heritable and non-genetic factors as variables of pharmacologic phenotypes in lymphoblastoid cell lines. Pharmacogenomics J. 2010 Dec; 10(6):505-12.
    View in: PubMed
    Score: 0.053
  32. Population-specific GSTM1 copy number variation. Hum Mol Genet. 2009 Jan 15; 18(2):366-72.
    View in: PubMed
    Score: 0.048
  33. Genetically regulated expression underlies cellular sensitivity to chemotherapy in diverse populations. Hum Mol Genet. 2021 04 26; 30(3-4):305-317.
    View in: PubMed
    Score: 0.029
  34. Variants in WFS1 and Other Mendelian Deafness Genes Are Associated with Cisplatin-Associated Ototoxicity. Clin Cancer Res. 2017 07 01; 23(13):3325-3333.
    View in: PubMed
    Score: 0.021
  35. Pharmacogenetic Discovery in CALGB (Alliance) 90401 and Mechanistic Validation of a VAC14 Polymorphism that Increases Risk of Docetaxel-Induced Neuropathy. Clin Cancer Res. 2016 Oct 01; 22(19):4890-4900.
    View in: PubMed
    Score: 0.020
  36. Association of an inherited genetic variant with vincristine-related peripheral neuropathy in children with acute lymphoblastic leukemia. JAMA. 2015 Feb 24; 313(8):815-23.
    View in: PubMed
    Score: 0.019
  37. Pharmacokinetics and pharmacogenomics of daunorubicin in children: a report from the Children's Oncology Group. Cancer Chemother Pharmacol. 2014 Oct; 74(4):831-8.
    View in: PubMed
    Score: 0.018
  38. Identification and validation of genetic variants that influence transcription factor and cell signaling protein levels. Am J Hum Genet. 2014 Aug 07; 95(2):194-208.
    View in: PubMed
    Score: 0.018
  39. Linking the genetic architecture of cytosine modifications with human complex traits. Hum Mol Genet. 2014 Nov 15; 23(22):5893-905.
    View in: PubMed
    Score: 0.018
  40. Identification of genetic variants associated with capecitabine-induced hand-foot syndrome through integration of patient and cell line genomic analyses. Pharmacogenet Genomics. 2014 May; 24(5):231-7.
    View in: PubMed
    Score: 0.018
  41. Chemotherapy-induced peripheral neurotoxicity and ototoxicity: new paradigms for translational genomics. J Natl Cancer Inst. 2014 Mar 12; 106(5).
    View in: PubMed
    Score: 0.017
  42. Cancer pharmacogenomics: strategies and challenges. Nat Rev Genet. 2013 Jan; 14(1):23-34.
    View in: PubMed
    Score: 0.016
  43. Copy number polymorphisms and anticancer pharmacogenomics. Genome Biol. 2011; 12(5):R46.
    View in: PubMed
    Score: 0.014
  44. An integrated genomic approach to the assessment and treatment of acute myeloid leukemia. Semin Oncol. 2011 Apr; 38(2):215-24.
    View in: PubMed
    Score: 0.014
  45. Germline polymorphisms discovered via a cell-based, genome-wide approach predict platinum response in head and neck cancers. Transl Res. 2011 May; 157(5):265-72.
    View in: PubMed
    Score: 0.014
  46. Comprehensive evaluation of the contribution of X chromosome genes to platinum sensitivity. Mol Cancer Ther. 2011 Mar; 10(3):472-80.
    View in: PubMed
    Score: 0.014
  47. Testicular cancer survivorship: research strategies and recommendations. J Natl Cancer Inst. 2010 Aug 04; 102(15):1114-30.
    View in: PubMed
    Score: 0.014
  48. SCAN: SNP and copy number annotation. Bioinformatics. 2010 Jan 15; 26(2):259-62.
    View in: PubMed
    Score: 0.013
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.